| Biomarker ID | 1064 |
| PMID | 23377530 |
| Year | 2013 |
| Biomarker | miR-141 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Bone Metastasis |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific |
| Experiment | Patients with Bone Metastasis Vs No Bone Metastasis |
| Type of Biomarker | Prognostic |
| Cohort | 10 patients with Benign Prostatic Hyperplasia (BPH), 20 with Local Prostate Cancer, 30 with bone-metastatic PCa (10 with hormone-naive PCa (HNPC) , 10 with hormone-sensitive PCa (HSPC) and 10 with hormone-refractory PCa (HRPC)) were taken for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-141 |